Piper Sandler analyst Christopher Raymond downgraded Oncorus to Neutral from Overweight with a price target of $2, down from $6.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ONCR:
- Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
- Oncorus announces reprioritization of lead product candidate ONCR-021
- Oncorus to Participate in Upcoming Investor Conferences
- Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
- Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer